{"task_id": "e752d71832953920", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 348/464)", "text": "A\nSPECIFIC ENTITIES (CONT\u2019D)\nDiabetes Mellitus\n339\n\n--- Page 361 ---\nLONG TERM MANAGEMENT (CONT\u2019D)\nreductase inhibitor (# LDL), bile acid sequestrants\n(# LDL), nicotinic acid (# triglycerides, # LDL, \" HDL\nbut may \" glucose)\n\u0002 DIABETIC\nCONTROL\naim\nfor\nHbA1C\nof\nless\nthan 7.0% in all patients. A target HbA1C of\n\u00056.5% may be considered in selected patients.\nFasting and before meals glucose should be\n4.0 7.0 mmol/L [73 126 mg/dL]. The 2 h post\nprandial glucose ideally should be 5.0 10.0 mg/\ndL [91 182 mg/dL] or 5.0 8.0 mg/dL [91 145 mg/\ndL] if A1C targets are not met). Diabetes Control\nand Complications Trial showed that intensive gly\ncemic control of patients with type 1 diabetes\nreduces retinopathy, nephropathy, and neuropa\nthy. A1C correlates with complications. Major side\neffects include 3\u0003 \" in hypoglycemia (especially\nprevious episodes, hypoglycemia unawareness)\nand increased weight gain\n\u0002 EDUCATION\nall patients should attend diabetes\nclasses\n\u0002 EXERCISE\n150 min per week of moderate to vig\norous aerobic physical activity and resistance exer\ncise 3 times per week. A baseline ECG or exercise\nECG is advisable prior to embarking on an exercise\nprogram\n\u0002 EYE/NEUROLOGIC\nall patients with type 2 diabetes\nshould be referred to an ophthalmologist at the\ntime of diagnosis and then annually. Patients with\ntype 1 diabetes may have a baseline eye assess\nment 5 years after the diagnosis as long as they are\naged 15 or greater. Eye exams may be done\nannually after that. All patients should have an\nannual assessment of neuropathy including the\ndiabetic foot exam. Amitriptyline, gabapentin, or\npregabalin may be used for painful neuropathy.\nDomperidone, metoclopramide, erythromycin, or\ncisapride (beware long QT) may be used for\ngastroparesis\n\u0002 FAT\nREDUCTION (lose 5 10 kg)\nall patients\nshould follow healthy eating guidelines and\ntry to attain an ideal body weight. See OBESITY\nISSUES (p. 403)\n\u0002 GET GOING TO QUIT SMOKING!\nthere are many\ndifferent options for patients, including nicotine\ngum, nicotine inhaler, Nicoderm patch, Bupro\npion SR, and varenicline. Smoking cessation\nclasses\n\u0002\nSCREENING FOR CARDIOVASCULAR DISEASE\npatients\nshould have the following tests done at baseline if\nthey meet any of the following criteria:\n\u0002 ECG\nif age >40, have had diabetes for >15\nyears, or if they have hypertension, proteinuria,\nreduced pulses or vascular bruits. ECG should be\nrepeated every 2 years in patients of high car\ndiovascular risk\nLONG TERM MANAGEMENT (CONT\u2019D)\n\u0002\nEXERCISE ECG\nSTRESS\nTEST\nangina, atypical\nchest pain, dyspnea, abnormal ECG, peripheral\nartery disease, carotid bruits, transient ischemic\nattack, and stroke\n\u0002\nSTRESS MIBI\nindividuals with an abnormal ECG\n(LBBB or ST T wave changes) or who cannot\nexercise\n\u0002\nREVASCULARIZATION\nprompt\nrevascularization\nvs medical therapy for stable ischemia seems\nto have similar outcomes (death and major\ncardiovascular events)\nORAL HYPOGLYCEMIC AGENTS\nBIGUANIDES (# hepatic glucose production, \" tissue\nsensitivity)\nmetformin 500 850 mg PO TID; adverse\neffects include GI upset and lactoacidosis; contraindi\ncations include hypoxia, hepatic and renal failure, HF,\npoor LV function; hold before giving IV contrast and\n48 h post contrast\nTHIAZOLIDINEDIONES (sensitizes tissues to insulin, #\nhepatic glucose production)\npioglitazone 15 45 mg\nPO daily; adverse effects include hepatotoxicity and\nfluid retention, contraindications include liver failure,\nfluid overload, HF, and CAD; avoid concurrent use of\ninsulin and thiazolidinediones as increased fluid reten\ntion. Recent evidence linking rosiglitazone with\nincreased risk of myocardial infarction and cardiovas\ncular death; thus the decision to prescribe rosiglita\nzone should be done after carefully balancing the risks\nand benefits of treatment. Rosiglitazone has been\nwithdrawn from the European market\nMEGLITINIDE (\" pancreatic insulin release)\nrepagli\nnide 0.5 4 mg PO TID ac meals; adverse effects\ninclude hypoglycemia\nSULFONYLUREA (\" pancreatic insulin release)\ngli\nclazide 80 mg PO daily to 160 mg BID; glimepiride\n1 8 mg PO daily, glyburide 2.5 10 mg PO BID;\nadverse effects include hypoglycemia\na GLUCOSIDASE\nINHIBITOR\n(delays\nglucose\nabsorption)\nacarbose 25 100 mg TID ac meals;\nadverse effects include bloating and diarrhea\nINCRETIN MIMETICS AND DIPEPTIDYL PEPTI\nDASE 4\n(DPP 4)\nINHIBITORS\nsitagliptin\n25 100 mg PO daily. Increases incretin levels,\nincreases insulin release in response to glucose, and\ndecreases glucagon resulting in improved postpran\ndial control; weight neutral; long term adverse effects\nare not yet known\nGLUCAGON LIKE\nPEPTIDE 1\n(GLP 1)\nANALO\nGUES\nexenatide 5 10 mg SC BID 30 min before\nmeals. Causes dose dependent and glucose depen\ndent insulin secretion, delays gastric emptying, pro\nmotes weight loss, and suppresses glucagon. Long\nterm adverse effects are unknown. Nausea is a com\nmon adverse effect and pancreatitis has been reported\n340\nDiabetes Mellitus", "text_length": 4907, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 348/464)", "type": "chunk", "chunk_index": 347, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.726977", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.727828", "status": "complete", "chunks_added": 3}